メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
林 宏樹
医学部・腎臓内科学
h-index
690
被引用数
14
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1999 …
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(88)
類似のプロファイル
(6)
フィンガープリント
Hiroki Hayashiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Cohort Analysis
74%
Nephrotic Syndrome
70%
Prospective Cohort Study
67%
Nephropathy
65%
Renal Biopsy
61%
Lupus Nephritis
59%
All Cause Mortality
54%
Chronic Kidney Disease
54%
Proteinuria
50%
Kidney Function
50%
Minimal Change Disease
50%
Nephrology
49%
End Stage Renal Disease
48%
Acute Kidney Injury
45%
Retrospective Cohort Study
45%
Immunoglobulin G4
44%
Polycystic Kidney Disease
44%
Cardiovascular System
42%
Disease
42%
Urinary System
37%
Hazard Ratio
35%
Proportional Hazards Model
35%
Creatinine
32%
Membranous Glomerulonephritis
27%
Infection
26%
Myeloperoxidase
24%
Diabetic Nephropathy
24%
Glomerular Filtration Rate
23%
Immunosuppressive Treatment
22%
Pediatrics
19%
Blood Purification
19%
Focal Segmental Glomerulosclerosis
19%
Immunoglobulin A Nephropathy
18%
ANCA Associated Vasculitis
18%
Glucocorticoid
18%
Fibrosis
17%
Interstitial Nephritis
16%
Serum Albumin
16%
Combination Therapy
16%
Human Study
16%
Ischemic Heart Disease
16%
Elderly Patient
16%
Cyclophosphamide
16%
Retrospective Study
15%
Patient with Alzheimer's Disease
14%
Short Term Survival
14%
Chromosome Protein
14%
Spinal Cord Tumor
14%
Nephrosclerosis
14%
Brain Natriuretic Peptide
14%
Pharmacology, Toxicology and Pharmaceutical Science
Prospective Cohort Study
100%
Cohort Study
99%
Chronic Kidney Failure
72%
All Cause Mortality
66%
Nephrotic Syndrome
63%
Remission
60%
Acute Kidney Failure
49%
Proteinuria
48%
Infection
41%
Kidney Disease
36%
Disease
30%
Immunoglobulin G4
29%
Ascites
29%
Kidney Polycystic Disease
29%
Tolvaptan
29%
End Stage Renal Disease
28%
Creatinine
27%
Membranous Glomerulonephritis
27%
Immunosuppressive Agent
23%
Focal Glomerulosclerosis
19%
Combination Therapy
18%
Renin
18%
Angiotensin
18%
Human Study
17%
Ischemic Heart Disease
16%
Short Term Survival
14%
Cyclophosphamide
14%
Retrospective Study
14%
Anemia
14%
Ferrous Sulfate
14%
Dapagliflozin
14%
Hyperuricemia
14%
Antihypertensive Agent
14%
Nephrotoxicity
14%
Brain Natriuretic Peptide
14%
Neutrophil Gelatinase Associated Lipocalin
14%
Antianemic Agent
14%
Alzheimer's Disease
14%
Vitamin D Receptor
14%
Uric Acid
14%
Moraxella
14%
Bacterial Arthritis
14%
Endocarditis
14%
Nephrosclerosis
14%
Inflammation
14%
Amyloid
14%
Sodium Glucose Cotransporter 2 Inhibitor
14%
Glucocorticoid
14%
Disease Course
14%
Hypotension
14%
Keyphrases
Remission of Proteinuria
44%
Dialysis Initiation
36%
Minimal Change Disease
36%
Multicenter Cohort Study
32%
Acute Kidney Injury
31%
Japan
29%
Incident Dialysis Patients
29%
Clinical Practice Guidelines
29%
Steroid-sensitive
29%
Retrospective Cohort Study
29%
All-cause Mortality
23%
Nephrotic Syndrome
22%
Hazard Ratio
20%
Blood Purification
19%
Infection-related Mortality
19%
Confidence Interval
19%
Prospective Cohort Study
18%
Adult Patients
17%
Infection Risk
14%
Acute Kidney Injury Network Criteria
14%
Short-term Survival
14%
High Mobility Group Box 1 (HMGB1)
14%
IgG4-related Kidney Disease
14%
Early Dialysis
14%
Intravenous Cyclophosphamide
14%
Renal Hypoperfusion
14%
Pressure-induced
14%
Rare Complication
14%
Periaortitis
14%
Spinal Epidural Tumor
14%
Ferrous Sulfate
14%
Ferric Citrate
14%
Regional Variation
14%
Serum Uric Acid
14%
Hyperuricemia
14%
Tocilizumab
14%
Skin Ulcer
14%
Racial Heterogeneity
14%
Sodium Zirconium Cyclosilicate
14%
Early Remission
14%
Purifier
14%
Moraxella Lacunata
14%
Septic Arthritis
14%
Tertiary Level
14%
Endocarditis
14%
Systematic Lupus Erythematosus
14%
Short-acting
14%
Giant Cell Arteritis
14%
IgG4-related Tubulointerstitial Nephritis
14%
Infiltration Rate
14%
